Praxis Precision Medicines provides update on clinical stage portfolio

Praxis Precision Medicines provided an update on its portfolio and planned key milestones in 2024: Topline results of PRAX-628 in Phase 2a PPR study in the first quarter of 2024, followed by the expected initiation of the Phase 2b study in focal epilepsy in 2024; Topline results for both Phase 3 studies evaluating ulixacaltamide in essential tremor in the second half of 2024; Complete regulatory interactions to advance elsunersen towards a pivotal study for the treatment of SCN2A gain-of-function developmental epilepsies; Topline results of the Phase 2 EMBOLD study of PRAX-562 in SCN2A and SCN8A developmental epilepsies in the first half of 2024. “We are thrilled to continue building on the momentum of an exciting 2023 and start the year with four assets in the clinic, including our lead program, ulixacaltamide, and PRAX-628, which continues to show its potential as a best-in-class drug in epilepsy. The recently announced partnership with Tenacia extends ulixacaltamide’s reach to Greater China, underscoring our commitment to realize the global value of our programs,” said Marcio Souza, president and chief executive officer.